The Supervisory Board of Eesti Energia has approved the Group’s strategy up to 2030 and beyond. The Group aims to ensure a secure, competitive energy supply while transforming the green transition into commercial growth.

To this end, the Group will focus on meeting growing demand for electricity, developing a balanced energy asset portfolio and strengthening its investment capacity to be ready to make the necessary investments in the future.

‘Eesti Energia’s role is to provide people and businesses with the assurance that energy is available, accessible and competitively priced. We channel our investments into projects where we see long-term value for our customers, Estonia’s energy security and the company. For new generation capacity, investments must be commercially viable and, where necessary, their profitability must be supported by appropriate measures,’ commented Andrus Durejko, Chairman of the Management Board of Eesti Energia.

Over the coming decade, the energy market will be shaped by electrification, the rapid expansion of renewable energy and the resulting rise in electricity price volatility. Renewable energy generation depends on the weather, which means that periods of very low and high prices will alternate more frequently in the market than before. This increases the need for dispatchable generation capacity, energy storage, flexibility solutions and a reliable electricity network to ensure that electricity is available even when renewable energy generation is low.

Eesti Energia’s core strength lies in its broad-based business model which brings generation, the electricity network, trading and customers together into an integrated value chain. This enables us to optimise energy assets and manage market fluctuations effectively. For customers, this means reliable and competitively priced energy, better price risk management and energy solutions tailored to their needs.

Four priorities up to 2030

Over the longer term, the company forecasts that growing electricity demand will drive the need for new dispatchable and flexible generation and storage solutions. In light of this, the Group will be guided by four strategic priorities over the coming years:

Enabler of the energy transition. The Group aims to meet approximately two-thirds of the incremental electricity demand in Estonia by 2030. The focus will be on improving electricity network reliability, speeding up connections, and developing flexibility and long-duration energy storage solutions.

A balanced portfolio of energy assets. Eesti Energia plans to add up to 350 megawatts of cleaner dispatchable generation capacity to its portfolio (including gas-fired power plants) and make more efficient use of its existing energy assets. A balanced asset portfolio must combine renewable energy, cleaner dispatchable generation capacity, and storage and flexibility solutions to reduce environmental impact while safeguarding both energy security and security of supply.

A future-proof business. Eesti Energia will maintain strategic flexibility regarding new investments – depending on market developments, business growth may come from new generation capacity, business segments or emerging technologies. Investment decisions will be based on their commercial viability and their impact on the Group’s long-term competitiveness.

A value-creating and efficient organisation. In implementing the strategy, we will develop in-house expertise across future energy solutions, digitalisation, artificial intelligence and regulatory affairs to be an active driver of change in the energy system.

A profitable business creates opportunities to invest in the future

Following a period of large-scale investment that delivered substantial renewable generation capacity to the region, Eesti Energia will, over the coming years, focus on improving the profitability of its existing operations, managing its asset and customer portfolios more holistically, increasing cost efficiency and allocating capital to projects that generate long-term value.

According to Andrus Durejko, improving profitability is a prerequisite for Eesti Energia to fulfil its role in the energy system over the long term.

‘The energy sector requires substantial, long-term investment. To this end, Eesti Energia must be a financially robust company capable of investing even in a shifting market environment. In the near term, we are therefore focusing on increasing the value of our existing assets and driving efficiency. When it comes to new investments, we operate on the principle that growth must create value,’ Durejko said.

Maintaining strategic flexibility amid market uncertainty

In the longer term, the Group is transitioning towards a cleaner energy portfolio and gradually phasing out oil shale-based power generation. In parallel, Eesti Energia is focusing on making more efficient use of its existing oil shale assets and increasing their value, decoupling its electricity and shale oil businesses, and valorising ash and gangue.

As market, technology and regulatory developments may unfold differently than expected, the strategic plan will be reviewed regularly.

‘In the energy sector today, decisions spanning decades must be made in an environment where market, technological and regulatory trajectories cannot be predicted with absolute certainty. That is why we are not tying our strategy to any one specific technology or growth path. Our objective is to keep Eesti Energia robust and flexible enough to invest at the right time in the solutions that the Estonian energy system and our customers need,’ said Durejko.

‘For us, the energy transition does not mean having to choose between security of supply, price and the environment. Estonia needs all three. Eesti Energia’s role is to help shape an energy system that is cleaner, reliable and actively supports the competitiveness of the Estonian economy,’ Durejko added.

The Strategy 2030+ slides are available HERE.

The milestone delivery brings hydrogen fuel cell technology to heavy-duty port operations, supporting the Port of Tilbury’s transition toward lower-emission container handling

The Hyster hydrogen fuel cell ReachStacker at the Port of Tilbury

From left to right: Matt Lea, Hyster; David Housden, Forth Ports; Andy Darlington, Forth Ports; Paul Dale, Forth Ports; Andrew Bellamy, Briggs Equipment UK; Ellie Bourne, Briggs Equipment UK; Lucien Robroek, Hyster; Junior van Remortele, Hyster
From left to right: Matt Lea, Hyster; David Housden, Forth Ports; Andy Darlington, Forth Ports; Paul Dale, Forth Ports; Andrew Bellamy, Briggs Equipment UK; Ellie Bourne, Briggs Equipment UK; Lucien Robroek, Hyster; Junior van Remortele, Hyster

TILBURY, UK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Hyster and local authorized dealer, Briggs Equipment UK, announce the delivery of a hydrogen fuel cell-powered Hyster® ReachStacker to the Port of Tilbury in Essex, UK. This is the first hydrogen fuel cell (HFC) powered container handler to be deployed and fully operational in a real-world port application within the United Kingdom.

“Today is an important milestone in the history of the Port of Tilbury as we welcome the UK’s first hydrogen fuel cell ReachStacker into our busy container operations,” says David Housden, Head of Engineering and Procurement, Port of Tilbury. “Working in collaboration with our project partners Hyster and Briggs Equipment over the past two years, we are now delivering 100% green hydrogen-powered heavy lifting capability for our customers.”

Building on insights from previous pilot programs, including the HFC ReachStacker pilot from Valencia that concluded last year, Hyster and Nuvera have optimized and right-sized the fuel cell system. This Hyster ReachStacker is powered by a Nuvera 60kW fuel cell engine that converts hydrogen into electricity to support a 130kWh lithium-ion battery and incorporates standardized Hyster software architecture used across other Hyster electric products.

The innovative Hyster ReachStacker is expected to help the Port of Tilbury demonstrate a lower CO2 emissions footprint by more than 107,000 kilograms or 79,600 pounds of CO2 per year*. The Port of Tilbury is part of the Forth Ports Group, which is working toward achieving net zero greenhouse gas emissions by 2042.

“While eliminating tailpipe emissions has been the core driver of this pioneering collaboration, it was also critical to develop a solution that was up to the job and delivers performance and toughness comparable to an ICE-powered machine,” says Lucien Robroek, President of Global Big Trucks, Hyster. “We are looking forward to seeing the HFC-powered ReachStacker in action, tackling intense duty cycles and helping demonstrate how hydrogen fuel cell technology can support the future of high-intensity port operations while advancing the Port of Tilbury’s energy transition goals.”

High-pressure tanks will store 32kg of hydrogen on board, helping deliver long run times and operational productivity across a full 12-hour shift. The HFC ReachStacker can be refueled in less than 30 minutes and will operate entirely on green hydrogen, produced with an electrolyzer from GeoPura. Together, these capabilities will help demonstrate the potential of hydrogen fuel cell technology to support demanding port operations while advancing sustainability objectives.

“This pre-production trial marks a landmark moment for our business as we introduce leading alternative clean energy solutions into our port operations,” Housden adds. “The project is supported by on-site green hydrogen production, supply and refueling infrastructure from GeoPura and the ReachStacker demonstrates our commitment to decarbonizing our operations and our transition to more sustainable port logistics.”

As a trusted Briggs Equipment customer for many years, the Port of Tilbury will benefit from the same high level of dealer support it receives across its existing Hyster fleet. Briggs Equipment will provide front-line service and maintenance support for the ReachStacker, while Hyster’s Hypercare program delivers enhanced factory backing for this innovative application.

“We are thrilled to be part of this milestone and to welcome the UK’s first hydrogen fuel cell ReachStacker to the Port of Tilbury,” says Mike Parkin, Ports and Big Truck Director, Briggs Equipment UK. “Briggs has a strong, long-standing partnership with the Port of Tilbury, and we are proud to support their move toward a lower-carbon future. This innovative hydrogen project shows what is possible when sustainability and innovation combine, setting an industry benchmark and advancing efforts to cut CO2 emissions and transition to cleaner operations.”

Hyster experts will work closely with Briggs and the Port of Tilbury to support the hydrogen fuel cell and high-voltage systems, providing specialized technical expertise and on-site assistance throughout the project. This collaborative approach combines trusted dealer support with factory expertise, enabling the Port of Tilbury to evaluate hydrogen fuel cell technology in demanding port applications while maintaining operational productivity.

*Based on 40,000 liters of diesel consumption / year (average @ 2,500 annual hours) and CO2 emission factor of 2.68 kilograms of CO2 / liter diesel (tank-to-wheel)

Images
For images, click here. 

ABOUT HYSTER

Hyster is a leading worldwide provider of Hyster® forklift truck and container handling solutions for the toughest, most intense industries on earth. The company designs and manufactures an industry leading, comprehensive range of material handling equipment, meeting the unique demands of everything from fast-paced industrial warehouses and manufacturing facilities to the most demanding, heavy-duty applications like ports and terminals. Backed by a dedicated, global dealer network and nearly a century of material handling experience, Hyster is the trusted resource customers can count on for technology tough enough for their worksites and proven solutions that keep critical operations moving.

Hyster Company is a division of Hyster-Yale Materials Handling, Inc., a wholly owned subsidiary of Hyster-Yale, Inc. (NYSE:HY) which is headquartered in Cleveland, Ohio and operates globally.

©2026 Hyster-Yale Materials Handling, Inc., all rights reserved. Hyster is a trademark of Hyster-Yale Materials Handling, Inc.

Attachment

CONTACT: Jennifer Timblin
Hyster
252-412-4322
jennifer.timblin@hyster-yale.com

Jude Mitcham
Molokini Marketing Ltd
+44 (0) 1903 207408
jude@molokini.co.uk

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) — BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the September 2026 cash distributions for the iShares ETFs listed on the TSX or Cboe Canada which pay on a monthly or quarterly basis. Unitholders of record of the applicable iShares ETF on September 24, 2026 will receive cash distributions payable in respect of that iShares ETF on September 29, 2026.

Details regarding the “per unit” distribution amounts are as follows:

Fund Name Fund
Ticker
Cash
Distribution
Per Unit
iShares 1-10 Year Laddered Corporate Bond Index ETF CBH $0.052
iShares 1-5 Year Laddered Corporate Bond Index ETF CBO $0.056
iShares S&P/TSX Canadian Dividend Aristocrats Index ETF CDZ $0.114
iShares Equal Weight Banc & Lifeco ETF CEW $0.066
iShares Global Real Estate Index ETF CGR $0.196
iShares International Fundamental Index ETF CIE $0.133
iShares Global Infrastructure Index ETF CIF $0.266
iShares 1-5 Year Laddered Government Bond Index ETF CLF $0.036
iShares 1-10 Year Laddered Government Bond Index ETF CLG $0.039
iShares US Fundamental Index ETF CLU $0.119
iShares US Fundamental Index ETF CLU.C $0.195
iShares S&P/TSX Canadian Preferred Share Index ETF CPD $0.059
iShares Canadian Fundamental Index ETF CRQ $0.179
iShares US Dividend Growers Index ETF (CAD-Hedged) CUD $0.096
iShares Convertible Bond Index ETF CVD $0.074
iShares Global Water Index ETF CWW $0.214
iShares Global Monthly Dividend Index ETF (CAD-Hedged) CYH $0.076
iShares Canadian Financial Monthly Income ETF FIE $0.040
iShares ESG Balanced ETF Portfolio GBAL $0.253
iShares ESG Conservative Balanced ETF Portfolio GCNS $0.263
iShares ESG Equity ETF Portfolio GEQT $0.176
iShares ESG Growth ETF Portfolio GGRO $0.222
iShares Equity + Bitcoin ETF Portfolio IBQT $0.089
iShares U.S. Aggregate Bond Index ETF XAGG $0.119
iShares U.S. Aggregate Bond Index ETF(1) XAGG.U $0.085
iShares U.S. Aggregate Bond Index ETF (CAD-Hedged) XAGH $0.120
iShares Core Balanced ETF Portfolio XBAL $0.162
iShares Core Canadian Universe Bond Index ETF XBB $0.081
iShares Core Canadian Corporate Bond Index ETF XCB $0.070
iShares ESG Advanced Canadian Corporate Bond Index ETF XCBG $0.127
iShares U.S. IG Corporate Bond Index ETF XCBU $0.124
iShares U.S. IG Corporate Bond Index ETF(1) XCBU.U $0.088
iShares Canadian Growth Index ETF XCG $0.112
iShares Core Conservative Balanced ETF Portfolio XCNS $0.154
iShares S&P/TSX SmallCap Index ETF XCS $0.191
iShares ESG Advanced MSCI Canada Index ETF XCSR $0.504
iShares Canadian Value Index ETF XCV $0.392
iShares Core MSCI Global Quality Dividend Index ETF XDG $0.075
iShares Core MSCI Global Quality Dividend Index ETF(1) XDG.U $0.053
iShares Core MSCI Global Quality Dividend Index ETF (CAD-Hedged) XDGH $0.059
iShares Core MSCI Canadian Quality Dividend Index ETF XDIV $0.120
iShares Core MSCI US Quality Dividend Index ETF XDU $0.150
iShares Core MSCI US Quality Dividend Index ETF(1) XDU.U $0.107
iShares Core MSCI US Quality Dividend Index ETF (CAD-Hedged) XDUH $0.055
iShares Canadian Select Dividend Index ETF XDV $0.124
iShares J.P. Morgan USD Emerging Markets Bond Index ETF (CAD-Hedged) XEB $0.059
iShares S&P/TSX Capped Energy Index ETF XEG $0.173
iShares S&P/TSX Composite High Dividend Index ETF XEI $0.114
iShares Jantzi Social Index ETF XEN $0.209
iShares Core Equity ETF Portfolio XEQT $0.102
iShares ESG Aware MSCI Canada Index ETF XESG $0.225
iShares Core Canadian 15+ Year Federal Bond Index ETF XFLB $0.116
iShares Flexible Monthly Income ETF XFLI $0.191
iShares Flexible Monthly Income ETF(1) XFLI.U $0.138
iShares Flexible Monthly Income ETF (CAD-Hedged) XFLX $0.180
iShares S&P/TSX Capped Financials Index ETF XFN $0.153
iShares Floating Rate Index ETF XFR $0.043
iShares Core Canadian Government Bond Index ETF XGB $0.051
iShares Global Government Bond Index ETF (CAD-Hedged) XGGB $0.043
iShares Core Growth ETF Portfolio XGRO $0.130
iShares Canadian HYBrid Corporate Bond Index ETF XHB $0.077
iShares U.S. High Dividend Equity Index ETF (CAD-Hedged) XHD $0.074
iShares U.S. High Dividend Equity Index ETF XHU $0.072
iShares U.S. High Yield Bond Index ETF (CAD-Hedged) XHY $0.084
iShares Core S&P/TSX Capped Composite Index ETF XIC $0.285
iShares U.S. IG Corporate Bond Index ETF (CAD-Hedged) XIG $0.073
iShares 1-5 Year U.S. IG Corporate Bond Index ETF (CAD-Hedged) XIGS $0.128
iShares Core Income Balanced ETF Portfolio XINC $0.161
iShares Core Canadian Long Term Bond Index ETF XLB $0.062
iShares S&P/TSX Capped Materials Index ETF XMA $0.064
iShares S&P/TSX Completion Index ETF XMD $0.182
iShares MSCI Min Vol USA Index ETF (CAD-Hedged) XMS $0.079
iShares MSCI USA Momentum Factor Index ETF XMTM $0.076
iShares MSCI Min Vol USA Index ETF XMU $0.200
iShares MSCI Min Vol USA Index ETF(1) XMU.U $0.145
iShares MSCI Min Vol Canada Index ETF XMV $0.344
iShares S&P/TSX North American Preferred Stock Index ETF (CAD-Hedged) XPF $0.066
iShares High Quality Canadian Bond Index ETF XQB $0.055
iShares MSCI USA Quality Factor Index ETF XQLT $0.069
iShares S&P/TSX Capped REIT Index ETF XRE $0.057
iShares ESG Aware Canadian Aggregate Bond Index ETF XSAB $0.050
iShares Core Canadian Short Term Bond Index ETF XSB $0.068
iShares Conservative Short Term Strategic Fixed Income ETF XSC $0.053
iShares Conservative Strategic Fixed Income ETF XSE $0.053
iShares Core Canadian Short Term Corporate Bond Index ETF XSH $0.063
iShares ESG Advanced 1-5 Year Canadian Corporate Bond Index ETF XSHG $0.124
iShares 1-5 Year U.S. IG Corporate Bond Index ETF XSHU $0.154
iShares 1-5 Year U.S. IG Corporate Bond Index ETF(1) XSHU.U $0.109
iShares Short Term Strategic Fixed Income ETF XSI $0.057
iShares Core Canadian 1-10 Year Bond Index ETF XSMB $0.104
iShares S&P/TSX Capped Consumer Staples Index ETF XST $0.099
iShares ESG Aware Canadian Short Term Bond Index ETF XSTB $0.047
iShares 0-5 Year TIPS Bond Index ETF (CAD-Hedged) XSTH $0.000
iShares 0-5 Year TIPS Bond Index ETF XSTP $0.000
iShares 0-5 Year TIPS Bond Index ETF(1) XSTP.U $0.000
iShares ESG Aware MSCI USA Index ETF XSUS $0.107
iShares 20+ Year U.S. Treasury Bond Index ETF (CAD-Hedged) XTLH $0.122
iShares 20+ Year U.S. Treasury Bond Index ETF XTLT $0.135
iShares 20+ Year U.S. Treasury Bond Index ETF(1) XTLT.U $0.096
iShares Core S&P Total U.S. Stock Market Index ETF (CAD-Hedged) XTOH $0.127
iShares Core S&P Total U.S. Stock Market Index ETF XTOT $0.114
iShares Core S&P Total U.S. Stock Market Index ETF(1) XTOT.U $0.083
iShares Diversified Monthly Income ETF XTR $0.040
iShares Core S&P U.S. Total Market Index ETF (CAD-Hedged) XUH $0.132
iShares S&P U.S. Financials Index ETF XUSF $0.271
iShares ESG Advanced MSCI USA Index ETF XUSR $0.189
iShares S&P/TSX Capped Utilities Index ETF XUT $0.091
iShares Core S&P U.S. Total Market Index ETF XUU $0.171
iShares Core S&P U.S. Total Market Index ETF(1) XUU.U $0.124
iShares MSCI USA Value Factor Index ETF XVLU $0.185

(1) Distribution per unit amounts are in U.S. dollars for XAGG.U, XCBU.U, XDG.U, XDU.U, XFLI.U, XMU.U, XSHU.U, XSTP.U, XTLT.U, XTOT.U and XUU.U.

Estimated September Cash Distributions for the iShares Premium Money Market ETF

The September cash distributions per unit for the iShares Premium Money Market ETF are estimated to be as follows:

Fund Name Fund
Ticker
Estimated
Cash
Distribution
Per Unit
iShares Premium Money Market ETF CMR $0.093

BlackRock Canada expects to issue a press release on or about September 23, 2026, which will provide the final amounts for the iShares Premium Money Market ETF.

Further information on the iShares ETFs can be found at http://www.blackrock.com/ca.

About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

About iShares ETFs
iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of more than 1,700 exchange traded funds (ETFs) and approximately $6.2 trillion in assets under management as of June 30, 2026, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.   

iShares® ETFs are managed by BlackRock Canada.

Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.

Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”). Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”). TSX is a registered trademark of TSX Inc. (“TSX”). All of the foregoing trademarks have been licensed to S&P Dow Jones Indices LLC and sublicensed for certain purposes to BlackRock Fund Advisors (“BFA”),  which in turn has sub-licensed these marks to its affiliate, BlackRock Asset Management Canada Limited (“BlackRock Canada”), on behalf of the applicable fund(s). The index is a product of S&P Dow Jones Indices LLC, and has been licensed for use by BFA and by extension, BlackRock Canada and the applicable fund(s). The funds are not sponsored, endorsed, sold or promoted by S&P Dow Jones Indices LLC, Dow Jones, S&P, any of their respective affiliates (collectively known as “S&P Dow Jones Indices”) or TSX, or any of their respective affiliates. Neither S&P Dow Jones Indices nor TSX make any representations regarding the advisability of investing in such funds.

MSCI is a trademark of MSCI, Inc. (“MSCI”). The ETF is permitted to use the MSCI mark pursuant to a license agreement between MSCI and BlackRock Institutional Trust Company, N.A., relating to, among other things, the license granted to BlackRock Institutional Trust Company, N.A. to use the Index. BlackRock Institutional Trust Company, N.A. has sublicensed the use of this trademark to BlackRock. The ETF is not sponsored, endorsed, sold or promoted by MSCI and MSCI makes no representation, condition or warranty regarding the advisability of investing in the ETF.

Contact for Media: 
Sydney Punchard
Email: Sydney.Punchard@blackrock.com 

The Magnum Ice Cream Company N.V.

(TMICC or the Company)

Annual General Meeting – Update Statement – Resolution 5 Voting Outcome

The Company provides this update statement on its engagement with shareholders following the Annual General Meeting (AGM) held on 7 May 2026. Whilst a clear majority of shareholders, 77.37%, voted in favour of Resolution 5 (Proposal to adopt the Foundation Plan for Growth); the UK Corporate Governance Code requires an update statement to be published where a resolution receives more than 20% of votes against.

The Board engaged extensively with shareholders and governance bodies as the Foundation Plan was developed, and continues to believe that it balances accountability, an ownership mindset, alignment with shareholder interests and long-term value creation. The Board also notes that it rightly carries downside risk for senior leaders from their direct co-investment. Through this detailed engagement, the Company developed a strong understanding of stakeholder views on the Foundation Plan and received support from a clear majority.

Following the AGM in May, the Board continued this process of engagement with shareholders and, taking into account this feedback, concluded that no further actions are necessary at this time.

The Board would like to thank all the shareholders who have engaged with the Company for their continuing feedback and support.  In line with its normal practice, the Board will continue to engage with shareholders and their representative bodies and will provide further updates in the Company’s 2026 Annual Report.

Enquiries  
Media Relations
media.relations-tmicc@magnumicecream.com

Investor Relations
investor.relations-tmicc@magnumicecream.com

About The Magnum Ice Cream Company

The Magnum Ice Cream Company N.V. EURONEXT: MICC/ NYSE: MICC/ LSE: MICC is the world’s leading ice cream business. Home to four of the world’s five largest ice cream brands: Magnum, Ben & Jerry’s, Cornetto and the Heartbrand, our portfolio delights consumers in 80 markets around the world. Headquartered in Amsterdam, The Netherlands, we have a global team of 19,000 employees, a network of 32 factories, 13 R&D centres, and a fleet of three million freezer cabinets. For more information, visit www.corporate.magnumicecream.com. TMICC’s legal entity identifier is 25490052LLF3XH6G9847.

The Magnum Ice Cream Company N.V.

(TMICC or the Company)

Annual General Meeting – Update Statement – Resolution 5 Voting Outcome

The Company provides this update statement on its engagement with shareholders following the Annual General Meeting (AGM) held on 7 May 2026. Whilst a clear majority of shareholders, 77.37%, voted in favour of Resolution 5 (Proposal to adopt the Foundation Plan for Growth); the UK Corporate Governance Code requires an update statement to be published where a resolution receives more than 20% of votes against.

The Board engaged extensively with shareholders and governance bodies as the Foundation Plan was developed, and continues to believe that it balances accountability, an ownership mindset, alignment with shareholder interests and long-term value creation. The Board also notes that it rightly carries downside risk for senior leaders from their direct co-investment. Through this detailed engagement, the Company developed a strong understanding of stakeholder views on the Foundation Plan and received support from a clear majority.

Following the AGM in May, the Board continued this process of engagement with shareholders and, taking into account this feedback, concluded that no further actions are necessary at this time.

The Board would like to thank all the shareholders who have engaged with the Company for their continuing feedback and support.  In line with its normal practice, the Board will continue to engage with shareholders and their representative bodies and will provide further updates in the Company’s 2026 Annual Report.

Enquiries  
Media Relations
media.relations-tmicc@magnumicecream.com

Investor Relations
investor.relations-tmicc@magnumicecream.com

About The Magnum Ice Cream Company

The Magnum Ice Cream Company N.V. EURONEXT: MICC/ NYSE: MICC/ LSE: MICC is the world’s leading ice cream business. Home to four of the world’s five largest ice cream brands: Magnum, Ben & Jerry’s, Cornetto and the Heartbrand, our portfolio delights consumers in 80 markets around the world. Headquartered in Amsterdam, The Netherlands, we have a global team of 19,000 employees, a network of 32 factories, 13 R&D centres, and a fleet of three million freezer cabinets. For more information, visit www.corporate.magnumicecream.com. TMICC’s legal entity identifier is 25490052LLF3XH6G9847.

Yale physician-scientist and biotech entrepreneur Dr. Ranjit Bindra brings deep expertise in DNA repair, synthetic lethality and brain tumor therapeutics

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Dr. Ranjit Bindra, MD, PhD, to its Scientific Advisory Board (“SAB”). Dr. Bindra is the Scientific Director of the Yale Brain Tumor Center and the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine.

“Dr. Bindra is a leader in the discovery, development and application of cancer therapies in the DNA-damage response field, and his appointment comes at an important moment for our Company,” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. “His laboratory has a track record of turning fundamental discoveries in DNA repair into biomarker-driven clinical trials, and he has founded multiple oncology companies, one of which was acquired by Merck in 2024. That combination of scientific depth and commercial execution is exactly what we want guiding our programs as we advance toward IND-enabling studies.”

Dr. Bindra’s research sits at the intersection of several areas central to Rakovina’s pipeline, including synthetic lethality in DNA repair-deficient tumors, the therapeutic application of PARP and ATR inhibition, and strategies designed to enable blood-brain barrier penetration. His group led the discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them highly sensitive to PARP inhibitors, work published in Nature, Nature Genetics, and Science Translational Medicine, and he is lead co-principal investigator of a 35-site, NCI-sponsored Phase II trial evaluating the PARP inhibitor olaparib in IDH1/2-mutant solid tumors.

“The central problem in treating brain tumors is not that we lack good targets, it is that most of the drugs we would want to use never reach them,” said Dr. Bindra. “Rakovina is pursuing DNA repair vulnerabilities with AI-designed molecules built from the outset to cross the blood-brain barrier. The team presented in vivo data on that approach at AACR this year. I have spent my career trying to move DNA repair biology out of the laboratory and into trials for patients who have very few options, and I am glad to be joining this team as it advances these programs toward the clinic.”

Dr. Bindra joins existing Scientific Advisory Board members Dr. Dennis Brown, PhD (Chair), Prof. Petra Hamerlik, Prof. Artem Cherkasov, and Dr. Leonard Post, PhD, each of whom brings decades of drug discovery and development experience to their advisory roles.

“Ranjit’s expertise is highly complementary to the work our team is doing across all three of our programs,” said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “He has published on the synergy between ATR inhibition and DNA-damaging agents, he treats brain tumor patients clinically, and he understands the delivery challenges that define this field. As we advance our brain-penetrant DDR inhibitor programs, having a clinician-scientist of his calibre in the room will sharpen how we prioritize and translate our science.”

About Prof. Ranjit Bindra, MD, PhD

Dr. Ranjit Bindra, MD, PhD is the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine and Scientific Director of the Yale Brain Tumor Center. A physician-scientist and radiation oncologist, he treats adult and pediatric patients with primary brain tumors and brain metastases using advanced radiation and radiosurgery.

His research focuses on uncovering fundamental DNA repair vulnerabilities in cancer and translating these discoveries into new therapies. His laboratory discovered that IDH1/2-mutant cancers harbor a profound defect in DNA repair that creates a powerful therapeutic vulnerability to PARP inhibition, work published in Nature, Nature Genetics, and Science Translational Medicine that has helped reshape the understanding of DNA repair targeting in cancer. More recently, his group reported a new strategy to exploit DNA repair defects through targeted DNA modification, published in Science, opening new avenues for therapeutic development.

Dr. Bindra is also an active biotech entrepreneur and has founded multiple biotechnology companies based on discoveries from his laboratory, including Cybrexa Therapeutics, Alphina Therapeutics, and Modifi Biosciences. Under his leadership as interim CEO, Modifi Biosciences was acquired by Merck in 2024.

He received his undergraduate degree from Yale University and his MD and PhD from the Yale School of Medicine and completed his residency and postdoctoral research training at Memorial Sloan Kettering Cancer Center.

Corporate Update

The Company would also like to provide the following corporate updates:

  • SR&ED tax refund: The Company received a gross Scientific Research and Experimental Development (SR&ED) tax refund of $920,846.10, including interest. Administered by the Canada Revenue Agency, SR&ED is Canada’s largest federal program supporting business research and development, providing tax incentives to companies that carry out experimental development and applied research within Canada. Rakovina’s refund reflects the scale of the Company’s research activity, which pairs AI-driven molecular design with laboratory validation at the University of British Columbia and the Vancouver Prostate Centre to develop novel inhibitors of the DNA-damage response. The funds will support advancement of Rakovina’s pipeline, including in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program, continued AI-driven lead optimization through the Company’s collaboration with Variational AI, advancement of the kt-3000 LNP formulation program, and ongoing kt-2000AI compound development.
  • Stock option grants: The Company’s board of directors has approved the grant of an aggregate of 2,910,500 stock options (the “Options”) to certain consultants, employees, officers and directors of the Company pursuant to the Company’s Long Term Incentive Plan. Each Option is exercisable at a price of $0.20 per common share and expires on the fifth anniversary of the grant date. The Options vest as to one quarter of each award every three months following the grant date, becoming fully vested one year after the grant date.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For Further Information Contact:

Kim Oishi
CEO
Kim.oishi@rakovinatherapeutics.com

Mark Mitchell
Director, IR & Communications
IR@rakovinatherapeutics.com

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.

Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.

Yale physician-scientist and biotech entrepreneur Dr. Ranjit Bindra brings deep expertise in DNA repair, synthetic lethality and brain tumor therapeutics

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Dr. Ranjit Bindra, MD, PhD, to its Scientific Advisory Board (“SAB”). Dr. Bindra is the Scientific Director of the Yale Brain Tumor Center and the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine.

“Dr. Bindra is a leader in the discovery, development and application of cancer therapies in the DNA-damage response field, and his appointment comes at an important moment for our Company,” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics. “His laboratory has a track record of turning fundamental discoveries in DNA repair into biomarker-driven clinical trials, and he has founded multiple oncology companies, one of which was acquired by Merck in 2024. That combination of scientific depth and commercial execution is exactly what we want guiding our programs as we advance toward IND-enabling studies.”

Dr. Bindra’s research sits at the intersection of several areas central to Rakovina’s pipeline, including synthetic lethality in DNA repair-deficient tumors, the therapeutic application of PARP and ATR inhibition, and strategies designed to enable blood-brain barrier penetration. His group led the discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them highly sensitive to PARP inhibitors, work published in Nature, Nature Genetics, and Science Translational Medicine, and he is lead co-principal investigator of a 35-site, NCI-sponsored Phase II trial evaluating the PARP inhibitor olaparib in IDH1/2-mutant solid tumors.

“The central problem in treating brain tumors is not that we lack good targets, it is that most of the drugs we would want to use never reach them,” said Dr. Bindra. “Rakovina is pursuing DNA repair vulnerabilities with AI-designed molecules built from the outset to cross the blood-brain barrier. The team presented in vivo data on that approach at AACR this year. I have spent my career trying to move DNA repair biology out of the laboratory and into trials for patients who have very few options, and I am glad to be joining this team as it advances these programs toward the clinic.”

Dr. Bindra joins existing Scientific Advisory Board members Dr. Dennis Brown, PhD (Chair), Prof. Petra Hamerlik, Prof. Artem Cherkasov, and Dr. Leonard Post, PhD, each of whom brings decades of drug discovery and development experience to their advisory roles.

“Ranjit’s expertise is highly complementary to the work our team is doing across all three of our programs,” said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. “He has published on the synergy between ATR inhibition and DNA-damaging agents, he treats brain tumor patients clinically, and he understands the delivery challenges that define this field. As we advance our brain-penetrant DDR inhibitor programs, having a clinician-scientist of his calibre in the room will sharpen how we prioritize and translate our science.”

About Prof. Ranjit Bindra, MD, PhD

Dr. Ranjit Bindra, MD, PhD is the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine and Scientific Director of the Yale Brain Tumor Center. A physician-scientist and radiation oncologist, he treats adult and pediatric patients with primary brain tumors and brain metastases using advanced radiation and radiosurgery.

His research focuses on uncovering fundamental DNA repair vulnerabilities in cancer and translating these discoveries into new therapies. His laboratory discovered that IDH1/2-mutant cancers harbor a profound defect in DNA repair that creates a powerful therapeutic vulnerability to PARP inhibition, work published in Nature, Nature Genetics, and Science Translational Medicine that has helped reshape the understanding of DNA repair targeting in cancer. More recently, his group reported a new strategy to exploit DNA repair defects through targeted DNA modification, published in Science, opening new avenues for therapeutic development.

Dr. Bindra is also an active biotech entrepreneur and has founded multiple biotechnology companies based on discoveries from his laboratory, including Cybrexa Therapeutics, Alphina Therapeutics, and Modifi Biosciences. Under his leadership as interim CEO, Modifi Biosciences was acquired by Merck in 2024.

He received his undergraduate degree from Yale University and his MD and PhD from the Yale School of Medicine and completed his residency and postdoctoral research training at Memorial Sloan Kettering Cancer Center.

Corporate Update

The Company would also like to provide the following corporate updates:

  • SR&ED tax refund: The Company received a gross Scientific Research and Experimental Development (SR&ED) tax refund of $920,846.10, including interest. Administered by the Canada Revenue Agency, SR&ED is Canada’s largest federal program supporting business research and development, providing tax incentives to companies that carry out experimental development and applied research within Canada. Rakovina’s refund reflects the scale of the Company’s research activity, which pairs AI-driven molecular design with laboratory validation at the University of British Columbia and the Vancouver Prostate Centre to develop novel inhibitors of the DNA-damage response. The funds will support advancement of Rakovina’s pipeline, including in vivo ADME and efficacy testing for the kt-5000AI dual ATR/mTOR inhibitor program, continued AI-driven lead optimization through the Company’s collaboration with Variational AI, advancement of the kt-3000 LNP formulation program, and ongoing kt-2000AI compound development.
  • Stock option grants: The Company’s board of directors has approved the grant of an aggregate of 2,910,500 stock options (the “Options”) to certain consultants, employees, officers and directors of the Company pursuant to the Company’s Long Term Incentive Plan. Each Option is exercisable at a price of $0.20 per common share and expires on the fifth anniversary of the grant date. The Options vest as to one quarter of each award every three months following the grant date, becoming fully vested one year after the grant date.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For Further Information Contact:

Kim Oishi
CEO
Kim.oishi@rakovinatherapeutics.com

Mark Mitchell
Director, IR & Communications
IR@rakovinatherapeutics.com

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:

This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.

Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.

LONDON, Sept. 17, 2026 (GLOBE NEWSWIRE) — Sompo International Holdings Ltd. today announced that Nicolas (Nic) Berg is appointed CEO of Sompo’s UK Insurance business, effective October 1, 2026, subject to regulatory approval. Mr Berg joins Sompo from SCOR Group where he was most recently CEO of SCOR US and Head of P&C North America.

Mr Berg succeeds Sarah Stanford who has led the UK Insurance business through its initial integration period following Sompo’s acquisition of Aspen. Ms Stanford is stepping down as CEO, UK Insurance on September 30.

Mr Berg will be based in London and will report to Alessa Quane, CEO of International Markets.

A highly experienced CEO, Mr. Berg spent much of his 25-year career at AIG in a succession of global and regional executive roles focused on the UK and European markets. Based in London, he served as Head of Liability and Financial Lines for the UK, Lloyd’s and EMEA, sat on the AIG Europe Ltd (UK) Executive Committee and chaired its Insurance Risk Committee. Mr. Berg has also led claims at scale, including as AIG Chief Claims Officer for North America.

Ms Quane said: “As an established insurance executive with deep industry knowledge and significant UK and global market experience, Nic brings a dynamic and forward-looking approach to leadership. He will play a critical role in advancing our strategy, accelerating our momentum and positioning Sompo as a leading commercial insurer in the UK market. I thank Sarah for her contributions and commitment and wish her all the best for the future.”

About Sompo 

We are Sompo, a global provider of commercial and consumer property, casualty, and specialty insurance and reinsurance. Building on the 138 years of innovation of our parent company, Sompo Holdings, Inc., Sompo employs approximately 10,000 people around the world who use their in-depth knowledge and expertise to help simplify and resolve your complex challenges. Because when you choose Sompo, you choose The Ease of Expertise™. 

“Sompo” refers to the brand under which Sompo International Holdings Ltd., a Bermuda-based holding company, together with its consolidated subsidiaries, operates its global property and casualty (re)insurance businesses. Sompo International Holdings Ltd. is an indirect wholly-owned subsidiary of Sompo Holdings, Inc., one of the leading property and casualty groups in the world with excellent financial strength as evidenced by ratings of A+ (Superior) from A.M. Best (XV size category) and A+ (Strong) from Standard & Poor’s. Shares of Sompo Holdings, Inc. are listed on the Tokyo Stock Exchange. 

To learn more please follow us on LinkedIn or visit sompo.com. 

Contact

Mike Jones
Global Head of Media Relations
M: +44 7765 901899
E: mijones@sompo-intl.com

LONDON, Sept. 17, 2026 (GLOBE NEWSWIRE) — Sompo International Holdings Ltd. today announced that Nicolas (Nic) Berg is appointed CEO of Sompo’s UK Insurance business, effective October 1, 2026, subject to regulatory approval. Mr Berg joins Sompo from SCOR Group where he was most recently CEO of SCOR US and Head of P&C North America.

Mr Berg succeeds Sarah Stanford who has led the UK Insurance business through its initial integration period following Sompo’s acquisition of Aspen. Ms Stanford is stepping down as CEO, UK Insurance on September 30.

Mr Berg will be based in London and will report to Alessa Quane, CEO of International Markets.

A highly experienced CEO, Mr. Berg spent much of his 25-year career at AIG in a succession of global and regional executive roles focused on the UK and European markets. Based in London, he served as Head of Liability and Financial Lines for the UK, Lloyd’s and EMEA, sat on the AIG Europe Ltd (UK) Executive Committee and chaired its Insurance Risk Committee. Mr. Berg has also led claims at scale, including as AIG Chief Claims Officer for North America.

Ms Quane said: “As an established insurance executive with deep industry knowledge and significant UK and global market experience, Nic brings a dynamic and forward-looking approach to leadership. He will play a critical role in advancing our strategy, accelerating our momentum and positioning Sompo as a leading commercial insurer in the UK market. I thank Sarah for her contributions and commitment and wish her all the best for the future.”

About Sompo 

We are Sompo, a global provider of commercial and consumer property, casualty, and specialty insurance and reinsurance. Building on the 138 years of innovation of our parent company, Sompo Holdings, Inc., Sompo employs approximately 10,000 people around the world who use their in-depth knowledge and expertise to help simplify and resolve your complex challenges. Because when you choose Sompo, you choose The Ease of Expertise™. 

“Sompo” refers to the brand under which Sompo International Holdings Ltd., a Bermuda-based holding company, together with its consolidated subsidiaries, operates its global property and casualty (re)insurance businesses. Sompo International Holdings Ltd. is an indirect wholly-owned subsidiary of Sompo Holdings, Inc., one of the leading property and casualty groups in the world with excellent financial strength as evidenced by ratings of A+ (Superior) from A.M. Best (XV size category) and A+ (Strong) from Standard & Poor’s. Shares of Sompo Holdings, Inc. are listed on the Tokyo Stock Exchange. 

To learn more please follow us on LinkedIn or visit sompo.com. 

Contact

Mike Jones
Global Head of Media Relations
M: +44 7765 901899
E: mijones@sompo-intl.com

FORM 8.5 (EPT/RI)

Amendment in 1(b)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Tribal Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Joint Broker to Tribal Group Plc
(d)        Date dealing undertaken: 16th September 2026

(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales

Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

Ordinary shares

Purchase

200,000

81.2 81.2

Ordinary shares

Sales

201,390

81.4 81.2

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 17th September 2026
Contact name: Priyali Bhattacharjee
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.